专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011118953A3 COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY OR LIPID RELATED METABOLIC DESEASES 审中-公开
标题翻译：预防或治疗肥胖或脂肪相关代谢性疾病的组合物
公开(公告)号：WO2011118953A3
公开(公告)日：2012-01-12
申请号：PCT/KR2011001945
申请日：2011-03-22
申请人： DONG A PHARM CO LTD , KIM SOON-HOE , SON MI-WON , LEE TAE-HO , SOHN YONG-SUNG , CHOI SANG-ZIN , BAEK NAM-JOON , JEONG JIN-SEOK , LEE SANG-JIN , LEE SEUL-KI
发明人： KIM SOON-HOE , SON MI-WON , LEE TAE-HO , SOHN YONG-SUNG , CHOI SANG-ZIN , BAEK NAM-JOON , JEONG JIN-SEOK , LEE SANG-JIN , LEE SEUL-KI
IPC分类号： A61K36/14 , A61P3/00 , A61P3/04
CPC分类号： A61K36/14
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of obesity or a lipid-related metabolic disease and a food for the amelioration or prevention of obesity or a lipid-related metabolic disease, containing an extract of at least one xylem selected from Thuja orientalis Linne xylem, Juniperus mexicana xylem and Thujopsis dolabrata xylem or (-)-thujopsene, as an active ingredient. The extract and (-)-thujopsene contained in the composition or food of the present invention exhibit significant body fat- and body weight-reducing effects and lowers plasma levels of glucose, GOT, GPT, LDL-cholesterol, and LDL/VLDL cholesterol. Accordingly, the composition and food of the present invention are effective for the treatment, amelioration or prevention of lipid-related metabolic diseases or obesity.
摘要翻译：本发明提供了一种用于预防或治疗肥胖或脂质相关代谢疾病的药物组合物和用于改善或预防肥胖或脂质相关代谢疾病的食物，其含有至少一种选自Thuja的木质部提取物东方栎木质部，桧木栎木质部和Thujopsis dolabrata木质部或（ - ） - thujopsene作为活性成分。包含在本发明的组合物或食品中的提取物和（ - ） - thujopsene显示出显着的身体脂肪和体重减轻作用并降低葡萄糖，GOT，GPT，LDL-胆固醇和LDL / VLDL胆固醇的血浆水平。因此，本发明的组合物和食品对于治疗，改善或预防与脂质有关的代谢性疾病或肥胖症是有效的。

2. 发明申请

WO2010095840A3 DONEPEZIL RESIN COMPLEX 审中-公开
标题翻译：丹尼尔树脂复合物
公开(公告)号：WO2010095840A3
公开(公告)日：2011-01-20
申请号：PCT/KR2010000947
申请日：2010-02-16
申请人： DONG A PHARM CO LTD , YOO MOOHI , CHA BONG JIN , KIM JEONG HOON , JUN JOON HO , KANG KYONG HOON
发明人： YOO MOOHI , CHA BONG JIN , KIM JEONG HOON , JUN JOON HO , KANG KYONG HOON
IPC分类号： C07D211/22 , A61K9/16 , C07D211/32
CPC分类号： C07D211/32 , A61K9/0056 , A61K31/445
摘要： The present invention relates to a donepezil resin complex consisting of donepezil or pharmaceutically acceptable salts thereof and a cation-exchange resin, and to oral preparations containing same. The complex of the present invention is advantageous in that it can effectively mask the unpleasant taste of donepezil or of the salts thereof, and therefore can be formulated into a variety of dosage forms such as a tablet, an orally disintegrating tablet, a troche tablet, a suspension, etc.
摘要翻译：本发明涉及由多奈哌齐或其药学上可接受的盐和阳离子交换树脂组成的多奈哌齐树脂复合物以及含有它们的口服制剂。本发明的复合物的优点在于它可以有效地掩盖多奈哌齐或其盐的令人不愉快的味道，因此可以配制成各种剂型，如片剂，口腔崩解片剂，锭剂片剂，暂停等

3. 发明申请

WO2012105767A3 ANTIARRHYTHMIC AGENT PREPARATIONS HAVING A PH-INDEPENDENT DISSOLUTION PROFILE 审中-公开
标题翻译：具有PH独立溶解度特征的抗菌药物制剂
公开(公告)号：WO2012105767A3
公开(公告)日：2012-10-26
申请号：PCT/KR2012000658
申请日：2012-01-30
申请人： DONG A PHARM CO LTD , KIM JEONG-HOON , JANG SUN-WOO , HAN SANG-DUG , JUNG SANG-WON
发明人： KIM JEONG-HOON , JANG SUN-WOO , HAN SANG-DUG , JUNG SANG-WON
IPC分类号： A61K31/343 , A61K9/16 , A61K9/20 , A61K9/48
CPC分类号： A61K31/343 , A61K9/146 , A61K9/1641 , A61K9/2031
摘要： The present invention relates to preparations containing dronedarone, which is an antiarrhythmic agent, and more particularly, to coprecipitated solid dispersions, or solids or liquids containing dronedarone, which enables a pH-independent dissolution profile, or the pharmaceutically acceptable salts thereof, and to preparations comprising the solid dispersions or solids or liquids. The solid dispersions or solids or liquids containing dronedarone according to the present invention maximize the dissolution of a main component in an acidic environment to improve dissolution in the event of fasting when the pH level is low, and maintain dronedarone in an extremely small particle or dissolved state when the environment is changed from the acidic environment into an alkaline environment, to thereby improve the low bioavailability of dronedarone or the salts thereof, or reduce the effects of food in terms of varying bioavailability depending on whether drugs are taken before or after a meal. Accordingly, the dronedarone preparations containing solid dispersions or solids or liquids according to the present invention may enable a patient to easily take drugs at any time before or after a meal, and may reduce the size of drugs to improve drug compliance.
摘要翻译：本发明涉及含有决奈罗隆的制剂，其是抗心律失常剂，更具体地说，涉及共沉淀的固体分散体，或含有决奈达隆的固体或液体，其使得不依赖于pH的溶出曲线，或其药学上可接受的盐和制剂包括固体分散体或固体或液体。根据本发明的含有决奈罗隆的固体分散体或固体或液体在酸性环境中使主要组分的溶解最大化，以在pH水平低时在禁食的情况下改善溶解，并且将决奈达隆保持在极小的颗粒中或溶解当环境从酸性环境变为碱性环境时，从而提高决奈达隆或其盐的低生物利用度，或者根据是否在饭前或服食后服用药物来降低食物在不同生物利用度方面的影响。因此，根据本发明的含有固体分散体或固体或液体的决奈达隆制剂可以使得患者能够在饭前或饭后容易地服用药物，并且可以减小药物的大小以改善药物依从性。

4. 发明申请

WO2012115402A3 CRYSTALLINE FORM OF DOCETAXEL AND PROCESS FOR PREPARATION THEREOF 审中-公开
标题翻译：多西他赛的晶体形式及其制备方法
公开(公告)号：WO2012115402A3
公开(公告)日：2012-10-18
申请号：PCT/KR2012001238
申请日：2012-02-20
申请人： DONG A PHARM CO LTD , SUNG SI-YOUNG , SON BYOUNG-HWA , RYU KI-MOON , KIM MOON-SUNG , KIM DONG-SUNG , KIM SOON-HOE
发明人： SUNG SI-YOUNG , SON BYOUNG-HWA , RYU KI-MOON , KIM MOON-SUNG , KIM DONG-SUNG , KIM SOON-HOE
IPC分类号： C07D305/14 , A61K31/337 , A61P35/00
CPC分类号： C07D305/14
摘要： The present invention relates to a novel anhydrous crystalline form of docetaxel. The novel anhydrous crystalline form of docetaxel according to the present invention is significant since it solves drawbacks the prior art such as stability and accompanying its relative substances increase. Moreover, the present invention provides a process for preparing the anhydrous crystalline form of docetaxel, which can solve the problems such as low yield, long processing time and low purity of the prior art. Also, the present invention provides a process for preparing the crystalline form of docetaxel trihydrates, which can solve the problems such as low yield, difficult reaction condition, long reaction time and time of drying. Therefore the crystalline form of docetaxel trihydrates is produced with the high yield in the mild condition by the process for preparing it.
摘要翻译：本发明涉及多西紫杉醇的新型无水结晶形式。根据本发明的新型多西紫杉醇无水结晶形式具有重要意义，因为它解决了现有技术的缺点，如稳定性及伴随其相关物质的增加。此外，本发明提供了一种制备多西他赛无水晶型的方法，其可以解决现有技术的产量低，处理时间长和纯度低的问题。本发明还提供了一种制备三水合多西紫杉醇结晶形式的方法，可以解决产率低，反应条件困难，反应时间长，干燥时间长等问题。因此，通过制备多西他赛三水合物的方法在温和条件下以高产率生产晶型多西紫杉醇三水合物。

5. 发明申请

WO2011052940A3 PROCESS FOR PREPARING CLOPIDOGREL HYDROGENSULFATE FORM I 审中-公开
标题翻译：制备氯吡格雷氢过硫酸盐的方法
公开(公告)号：WO2011052940A3
公开(公告)日：2011-10-20
申请号：PCT/KR2010007321
申请日：2010-10-25
申请人： DONG A PHARM CO LTD , KIM MOON-SUNG , YOO MOO-HI , KIM YONG-JIK , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON , SON BYOUNG-HWA , RYU KI-MOON
发明人： KIM MOON-SUNG , YOO MOO-HI , KIM YONG-JIK , CHOI JUN-HO , SUNG SI-YOUNG , LIM HONG-GYU , CHA DAE-WON , SON BYOUNG-HWA , RYU KI-MOON
IPC分类号： C07D495/04 , A61K31/519 , A61P9/10 , C07D495/02
CPC分类号： C07D495/04
摘要： The present invention relates to a process for preparing clopidogrel hydrogensulfate Form I having a large particle size and containing 0.1% or less impurities, and clopidogrel hydrogensulfate Form I produced thereby. The process of the present invention allows a clopidogrel hydrogensulfate Form I to have a pharmaceutically useful particle size and an even spherical form, and to contain 0.1% or less of impurities.
摘要翻译：制备氯吡格雷硫酸氢盐晶型I的方法本发明涉及一种制备氯吡格雷硫酸氢盐晶型I的方法，该方法具有较大的颗粒尺寸并且含有0.1％或更少的杂质，以及由此生产的氯吡格雷硫酸氢盐晶型I。本发明的方法允许硫酸氢氯吡格雷晶型I具有药学上有用的粒径和均匀的球形，并且含有0.1％或更少的杂质。

6. 发明申请

WO2010114292A2 IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 审中-公开
标题翻译：制备DIPEPTIDYP肽酶IV抑制剂和中间体的改进方法
公开(公告)号：WO2010114292A2
公开(公告)日：2010-10-07
申请号：PCT/KR2010001948
申请日：2010-03-30
申请人： DONG A PHARM CO LTD , KWAK WOO YOUNG , KIM HEUNG JAE , MIN JONG PIL , YOON TAE HYUN , SHIM HYUN JOO , YOO MOOHI
发明人： KWAK WOO YOUNG , KIM HEUNG JAE , MIN JONG PIL , YOON TAE HYUN , SHIM HYUN JOO , YOO MOOHI
IPC分类号： C07C213/00 , C07C219/06 , C07C219/18 , C07D239/10
CPC分类号： C07D203/18 , C07C269/06 , C07D265/32 , Y02P20/55 , C07C271/22
摘要： The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.
摘要翻译：本发明涉及二肽基肽酶-IV抑制剂和中间体的改进方法。本发明通过使低成本试剂反应，可以提高生产成本，提高产率，适用于批量生产。

7. 发明申请

WO2010114291A2 IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 审中-公开
标题翻译：制备DIPEPTIDYP肽酶IV抑制剂和中间体的改进方法
公开(公告)号：WO2010114291A2
公开(公告)日：2010-10-07
申请号：PCT/KR2010001947
申请日：2010-03-30
申请人： DONG A PHARM CO LTD , KWAK WOO YOUNG , KIM HEUNG JAE , MIN JONG PIL , YOON TAE HYUN , YOO MOOHI , LIM GEUN GHO , CHANG SUN KI
发明人： KWAK WOO YOUNG , KIM HEUNG JAE , MIN JONG PIL , YOON TAE HYUN , YOO MOOHI , LIM GEUN GHO , CHANG SUN KI
IPC分类号： C07C213/00 , C07C219/10 , C07C219/18 , C07D203/06
CPC分类号： C07D241/08 , C07C29/106 , C07C29/36 , C07C227/02 , C07C241/00 , C07C247/10 , C07C253/00 , C07C255/42 , C07C255/44 , C07C269/06 , C07C271/22 , C07D203/08 , C07D203/10 , C07D203/18 , Y02P20/55 , C07C33/46
摘要： The present invention relates to an improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention is able to reduce preparation costs by using low cost reagents on reaction and is able to be used in mass production by improving yield.
摘要翻译：本发明涉及二肽基肽酶-IV抑制剂和中间体的改进方法。本发明能够通过在反应中使用低成本试剂来降低制备成本，并且能够通过提高产率而用于批量生产。

8. 发明申请

WO2010095849A2 ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：醋酸的添加盐，其制备方法和包含其的药物组合物
公开(公告)号：WO2010095849A2
公开(公告)日：2010-08-26
申请号：PCT/KR2010000976
申请日：2010-02-17
申请人： DONG A PHARM CO LTD , LEE CHAN-HO , SHIN CHANG-YONG , CHOI SEUL-MIN , KANG KYUNG-KOO , KIM DONG-SEONG , AHN BYOUNG-OK , YOO MOO-HI
发明人： LEE CHAN-HO , SHIN CHANG-YONG , CHOI SEUL-MIN , KANG KYUNG-KOO , KIM DONG-SEONG , AHN BYOUNG-OK , YOO MOO-HI
IPC分类号： C07D487/04 , C07D487/02
CPC分类号： C07D487/04
摘要： The present invention provides an acid addition salt of Udenafil, a preparation method thereof and a pharmaceutical composition comprising the same. The acid addition salt of Udenafil in which Udenafil is bonded to an organic acid selected from the group consisting of oxalic acid, benzenesulfonic acid, camphorsulfonic acid, cinnamic acid, adipic acid and cyclamic acid, has excellent solubility in an aqueous medium, water stability and crystallinity, thereby being suitably applied for a pharmaceutical composition.
摘要翻译：本发明提供了Udenafil的酸加成盐，其制备方法和包含其的药物组合物。乌代那芬的酸加成盐，其中，阿登奈芬与选自草酸，苯磺酸，樟脑磺酸，肉桂酸，己二酸和环己烷氨基酸的有机酸结合，在水性介质中具有优异的溶解性，水稳定性和结晶度，从而适合用于药物组合物。

9. 发明申请

WO2010013925A3 PHARMACOLOGICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESPIRATORY DISEASE CONTAINING PYRAZOLOPYRIMIDINONE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF 审中-公开
标题翻译：用于预防和治疗含有吡唑并嘧啶酮化合物或药物可接受的药物的呼吸道疾病的药理学组合物
公开(公告)号：WO2010013925A3
公开(公告)日：2010-05-27
申请号：PCT/KR2009004188
申请日：2009-07-28
申请人： DONG A PHARM CO LTD , LEE CHAN HO , CHOI SEUL MIN , KIM DONG HWAN , KANG KYUNG KOO , KIM DONG SEONG , AHN BYOUNG OK , YOO MOOHI
发明人： LEE CHAN HO , CHOI SEUL MIN , KIM DONG HWAN , KANG KYUNG KOO , KIM DONG SEONG , AHN BYOUNG OK , YOO MOOHI
IPC分类号： C07D487/04 , A61K31/519 , A61P11/00 , C07D487/02
CPC分类号： A61K31/519 , A61K9/0075 , A61K9/0078 , A61K9/2018 , A61K9/4858 , C07D487/04
摘要： Disclosed herein is composition for prevention and treatment of respiratory disease containing a pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof as an active ingredient.
摘要翻译：本文公开了用于预防和治疗含有吡唑并嘧啶酮化合物或其药学上可接受的盐作为活性成分的呼吸系统疾病的组合物。

10. 发明申请

WO2010024586A2 NOVEL BENZAMIDE DERIVATIVE COMPOUND, AND A METHOD FOR PRODUCING SAME 审中-公开
标题翻译：新型苯甲酰衍生物及其生产方法
公开(公告)号：WO2010024586A2
公开(公告)日：2010-03-04
申请号：PCT/KR2009004754
申请日：2009-08-26
申请人： DONG A PHARM CO LTD , YOO MOOHI , RHEE JAEKEOL , IM WEONBIN , CHOI SUNGHAK , PARK JUNGSANG , CHOI SUNHO , SOHN TAEKYOUNG , SUNG HYUNJUNG , SOHN JUHEE , CHO KANGHUN
发明人： YOO MOOHI , RHEE JAEKEOL , IM WEONBIN , CHOI SUNGHAK , PARK JUNGSANG , CHOI SUNHO , SOHN TAEKYOUNG , SUNG HYUNJUNG , SOHN JUHEE , CHO KANGHUN
IPC分类号： C07D403/04
CPC分类号： C07D403/04
摘要： The present invention relates to a compound of the following chemical Formula I, isomers thereof or pharmaceutically acceptable salts of the compound and their isomers; to a production method for the compound and isomers thereof and to a pharmaceutical composition which is efficacious on 5-HT4 receptors and which contains the compound or an isomer thereof as an active principle.
摘要翻译：本发明涉及以下化学式I的化合物，其异构体或化合物的药学上可接受的盐及其异构体; 涉及化合物及其异构体的制备方法和对5-HT 4受体有效的药物组合物，其含有作为活性成分的化合物或其异构体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式